Ben Xi Shi

Researchers are evaluating whether Extract of Ginkgo Biloba Leaves Tablets can improve memory and thinking skills in people aged 55 and older who have had an ischemic stroke caused by a blocked blood vessel in the brain. This study also looks at the safety of taking these tablets alongside usual post-stroke treatments. Participants must have had a stroke confirmed by MRI within 7 to 14 days before joining the study and have mild cognitive impairment after their stroke. Participants will be randomly assigned to one of two groups one group will take 240 mg of Extract of Ginkgo Biloba Leaves Tablets daily for 12 months in addition to their usual stroke care, while the other group will receive only their usual care without the tablets. The study will take place at hospitals across China and will last for 52 weeks for each participant. Throughout the study, participants will visit the clinic at 4, 26, and 52 weeks after starting treatment for checkups and tests, including brain scans, cognitive assessments such as the Montreal Cognitive Assessment and other neuropsychological tests, and evaluations of neurological function. Follow-up phone calls will occur at 12 and 38 weeks to monitor health and any new stroke events. Researchers will measure changes in thinking, memory, cognitive speed, verbal skills, and neurological status to understand the tablets effects and safety over time.

Extensive intraductal carcinoma of the breast is a type of breast cancer where 25% or more of ductal carcinoma in situ DCIS is present within invasive tumors, often scattered around the invasive cancer. Patients with this condition are less responsive to radiotherapy and face higher risks of tumor recurrence after breast-conserving surgery compared to those without extensive DCIS. This study evaluates the postoperative disease-free survival and quality of life in patients undergoing two surgical treatments for this type of breast cancer modified radical mastectomy and expanded Mckissock surgery. The trial compares two surgical approaches. The expanded Mckissock surgery involves preserving the nipple-areola complex while removing the total gland, reshaping the breast using vertical subcutaneous pedicle flaps, and placing drainage tubes. This technique is applied based on imaging results and patient preferences. The modified radical mastectomy removes the breast tissue more extensively but also reshapes the breast with similar flap techniques and drainage. One hundred patients will be assigned to each group for comparison. Participants will be followed for five years to assess disease-free survival and quality of life using a breast cancer-specific questionnaire. Additional measurements include breast symmetry and medical costs during hospitalization. Assessments and monitoring occur throughout the follow-up period to evaluate the surgical outcomes and patient well-being after treatment. The study provides insight into the effectiveness and impact of these two surgical options for extensive intraductal carcinoma of the breast.

Researchers are studying whether using a drug-eluting stent DES combined with aggressive medical treatment is more effective at preventing stroke recurrence within one year compared to standard medical treatment alone in patients with symptomatic intracranial atherosclerotic disease. This prospective, multi-center trial randomly assigns participants to either the stent plus aggressive medication group or the standard treatment group to evaluate safety and stroke prevention outcomes. The study compares two groups one receiving the Maurora Sirolimus Eluting Stent implantation plus aggressive medical treatment, which includes aspirin daily throughout follow-up, clopidogrel or ticagrelor for six months, and management of risk factors like hypertension and diabetes the other receiving standard medical treatment with aspirin daily, clopidogrel or ticagrelor for three months, and similar risk factor management. The device used is a balloon-expandable sirolimus-eluting stent delivered via catheter. Follow-up lasts 12 months after enrollment. Participants will undergo regular assessments including monitoring for stroke or death within 30 days after enrollment or procedures, ischemic stroke occurrence up to one year, bleeding events, imaging to check for vessel narrowing, and functional status evaluations. Safety and effectiveness are closely tracked through clinical visits and tests over the 12-month period. The study aims to provide detailed data on stroke recurrence prevention and treatment safety in this patient population.

Researchers are evaluating the safety and effectiveness of edaravone dexborneol sublingual tablets for treating cognitive problems after a stroke in adults aged 40 to 80 years. This exploratory Phase II clinical trial is randomized, double-blind, and placebo-controlled, aiming to compare outcomes between patients receiving the study drug and those receiving a placebo. The study focuses on patients who have had an acute ischemic stroke and developed cognitive impairment. Participants will be randomly assigned to receive either edaravone dexborneol sublingual tablets or a placebo twice daily for 24 weeks. Both groups will follow the same treatment schedule over this period. The trial will monitor and compare the safety and effectiveness of the tablet by assessing cognitive function and other health measures. During the study, participants will undergo evaluations including cognitive tests such as the Vascular Dementia Assessment Scale-cognitive subscale, Mini-Mental State Examination, and Montreal Cognitive Assessment at various times up to 24 weeks. Researchers will also track adverse events, treatment discontinuations, and other stroke-related scales. The total follow-up period for safety monitoring extends to 26 weeks, including after treatment completion or early withdrawal.

Researchers are evaluating the safety, pharmacokinetics, and effectiveness of a drug called QD202 in adults with acute ischemic stroke who are receiving thrombolysis but not endovascular thrombectomy. This randomized, double-blinded, placebo-controlled phase II trial aims to better understand how QD202 works and is tolerated in this patient group. The study is sponsored by Shanghai QuietD Biotechnology Co., Ltd. and will include up to 120 male and female participants aged 18 to 85 years. Participants will be randomly assigned to one of three groups two experimental groups receiving different doses of QD202 100 mg on Day 1 followed by either 5 mg or 10 mg daily from Day 2 to Day 5 or a placebo group receiving a matching placebo daily for five days. The study drug or placebo is given as a 60-minute intravenous infusion after completion of thrombolysis. The trial includes a treatment period of five days and follow-up visits on Day 7 or discharge day, Day 30, and Day 90. During the study, participants will undergo assessments including stroke severity scales such as the National Institutes of Health Stroke Scale NIHSS, functional outcome measures like the modified Rankin Scale mRS and Barthel Index BI, and blood tests to monitor drug levels and safety. Safety and tolerance will be followed through Day 90. Participants will have multiple visits during this period for evaluations of their neurological status and overall health.

Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.